BRPI0411219A - seqüências de hbv e hcv conservadas úteis para silenciamento de gene - Google Patents
seqüências de hbv e hcv conservadas úteis para silenciamento de geneInfo
- Publication number
- BRPI0411219A BRPI0411219A BRPI0411219-9A BRPI0411219A BRPI0411219A BR PI0411219 A BRPI0411219 A BR PI0411219A BR PI0411219 A BRPI0411219 A BR PI0411219A BR PI0411219 A BRPI0411219 A BR PI0411219A
- Authority
- BR
- Brazil
- Prior art keywords
- hbv
- gene silencing
- useful
- hcv
- sequences useful
- Prior art date
Links
- 230000030279 gene silencing Effects 0.000 title abstract 3
- 238000012226 gene silencing method Methods 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 3
- 108091035707 Consensus sequence Proteins 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47807603P | 2003-06-12 | 2003-06-12 | |
| PCT/US2004/019229 WO2005014806A2 (en) | 2003-06-12 | 2004-06-10 | Conserved hbv and hcv sequences useful for gene silencing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0411219A true BRPI0411219A (pt) | 2006-07-18 |
Family
ID=34135047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0411219-9A BRPI0411219A (pt) | 2003-06-12 | 2004-06-10 | seqüências de hbv e hcv conservadas úteis para silenciamento de gene |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8350021B2 (OSRAM) |
| EP (4) | EP3470518A1 (OSRAM) |
| JP (2) | JP4980716B2 (OSRAM) |
| CN (1) | CN1836042A (OSRAM) |
| AU (1) | AU2004263832B2 (OSRAM) |
| BR (1) | BRPI0411219A (OSRAM) |
| CA (2) | CA3040025C (OSRAM) |
| DK (1) | DK2270162T3 (OSRAM) |
| HU (1) | HUE042261T2 (OSRAM) |
| IL (1) | IL172268A0 (OSRAM) |
| SG (1) | SG173218A1 (OSRAM) |
| SI (1) | SI2270162T1 (OSRAM) |
| WO (1) | WO2005014806A2 (OSRAM) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| BRPI0411219A (pt) | 2003-06-12 | 2006-07-18 | Nucleonics Inc | seqüências de hbv e hcv conservadas úteis para silenciamento de gene |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| JP5243789B2 (ja) | 2004-03-15 | 2013-07-24 | シティ・オブ・ホープ | 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための方法及び組成物 |
| WO2006033756A2 (en) | 2004-08-23 | 2006-03-30 | Nucleonics, Inc. | Multiple rna polymerase iii promoter expression constructs |
| ES2362670T3 (es) | 2004-09-24 | 2011-07-11 | Alnylam Pharmaceuticals, Inc | Orientación a intermedios de replicación de hebra no codificante de virus monocatenarios por arni. |
| WO2006069064A2 (en) * | 2004-12-22 | 2006-06-29 | Nucleonics, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| WO2011103394A2 (en) * | 2010-02-19 | 2011-08-25 | Agave Pharma Inc. | Methods for gene inhibition |
| AU2011223820B2 (en) | 2010-03-01 | 2016-01-14 | The Children's Hospital Of Philadelphia | Nucleic acids for targeting multiple regions of the HCV genome |
| EP3587574B1 (en) * | 2010-08-17 | 2022-03-16 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
| JP6042871B2 (ja) * | 2011-04-21 | 2016-12-14 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｂ型肝炎ウイルス（ｈｂｖ）発現の調節 |
| JP6270846B2 (ja) | 2012-08-30 | 2018-01-31 | レプリコール インコーポレーティッド | Ｂ型肝炎感染及びｄ型肝炎感染の治療方法 |
| EP3013362B1 (en) | 2013-06-28 | 2021-08-04 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
| EP3540051B1 (en) | 2013-12-12 | 2022-08-17 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hsv and viral diseases and disorders. |
| JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| KR20170141257A (ko) * | 2015-05-06 | 2017-12-22 | 베니텍 바이오파마 리미티드 | B형 간염 바이러스 (hbv) 감염의 치료를 위한 시약 및 이의 용도 |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| AU2016296592B2 (en) | 2015-07-17 | 2021-08-19 | Arcturus Therapeutics, Inc. | Compositions and agents against Hepatitis B virus and uses thereof |
| AR108038A1 (es) | 2016-03-14 | 2018-07-11 | Roche Innovation Ct Copenhagen As | Oligonucleótidos para reducir la expresión de pd-l1 (ligando de muerte programada-1) |
| MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
| CN111052249B (zh) * | 2017-09-15 | 2024-04-05 | 深圳华大智造科技股份有限公司 | 确定预定染色体保守区域的方法、确定样本基因组中是否存在拷贝数变异的方法、系统和计算机可读介质 |
| AU2018350693B2 (en) | 2017-10-16 | 2021-03-04 | F. Hoffmann-La Roche Ag | Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection |
| EP3775208A1 (en) | 2018-04-05 | 2021-02-17 | F. Hoffmann-La Roche AG | Use of fubp1 inhibitors for treating hepatitis b virus infection |
| MY206038A (en) | 2018-07-03 | 2024-11-26 | Hoffmann La Roche | Oligonucleotides for modulating tau expression |
| MX2021000404A (es) | 2018-07-13 | 2021-03-25 | Hoffmann La Roche | Oligonucleotidos para modular la expresion de rtel1. |
| UA127745C2 (uk) | 2018-08-13 | 2023-12-20 | Альнілам Фармасьютікалз, Інк. | КОМПОЗИЦІЇ, ЩО МІСТЯТЬ ЗАСІБ НА ОСНОВІ dsRNA ВІРУСУ ГЕПАТИТУ В (HBV), ТА СПОСОБИ ЇХ ВИКОРИСТАННЯ |
| CN114901821A (zh) | 2019-12-19 | 2022-08-12 | 豪夫迈·罗氏有限公司 | Sept9抑制剂用于治疗乙型肝炎病毒感染的用途 |
| JP2023506954A (ja) | 2019-12-19 | 2023-02-20 | エフ． ホフマン－ラ ロシュ エージー． | Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用 |
| EP4077670A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of cops3 inhibitors for treating hepatitis b virus infection |
| JP2023506550A (ja) | 2019-12-19 | 2023-02-16 | エフ． ホフマン－ラ ロシュ エージー． | Ｂ型肝炎ウイルス感染症を処置するためのｓｂｄｓ阻害剤の使用 |
| CN114829599A (zh) | 2019-12-19 | 2022-07-29 | 豪夫迈·罗氏有限公司 | Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途 |
| EP4200419A2 (en) | 2020-08-21 | 2023-06-28 | F. Hoffmann-La Roche AG | Use of a1cf inhibitors for treating hepatitis b virus infection |
| TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| JP2024546993A (ja) | 2021-12-17 | 2024-12-26 | エフ． ホフマン－ラ ロシュ アーゲー | Ｒｔｅｌ１及びｆｕｂｐ１を調節するためのオリゴヌクレオチドの組み合わせ |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643771A (en) | 1980-05-19 | 1997-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Non-reverting live bacterial vaccines |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| EP0400047B1 (en) | 1988-02-05 | 1997-04-23 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| CA2085353A1 (en) | 1990-06-18 | 1991-12-19 | Chandrakant P. Giri | Eukaryotic expression vector system |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| EP0759979A4 (en) * | 1994-05-10 | 1999-10-20 | Gen Hospital Corp | THE ANTISENSE INHIBITION OF HEPATITIS C VIRUS |
| JPH07303485A (ja) | 1994-05-13 | 1995-11-21 | Tonen Corp | Ｈｃｖアンチセンスｒｎａ、それを含む発現ベクター、及び該ｒｎａ又は発現ベクターを含むｈｃｖ関連疾患治療剤 |
| US5646262A (en) * | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5571026A (en) * | 1994-12-09 | 1996-11-05 | Kcs Industries, Inc. | Flat mount electrode socket |
| US6057153A (en) * | 1995-01-13 | 2000-05-02 | Yale University | Stabilized external guide sequences |
| US5877159A (en) | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
| US5932241A (en) | 1995-06-07 | 1999-08-03 | Valentis, Incorporated | Cationic lipid DNA complexes for gene targeting |
| US5824538A (en) | 1995-09-06 | 1998-10-20 | The United States Of America As Represented By The Secretary Of The Army | Shigella vector for delivering DNA to a mammalian cell |
| US5843770A (en) * | 1996-03-11 | 1998-12-01 | The Immune Response Corporation | Antisense constructs directed against viral post-transcriptional regulatory sequences |
| US5877162A (en) * | 1996-03-14 | 1999-03-02 | Innovir Laboratories, Inc. | Short external guide sequences |
| US6610478B1 (en) * | 1996-08-16 | 2003-08-26 | Yale University | Phenotypic conversion of cells mediated by external guide sequences |
| US5981274A (en) * | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| DE19725803C1 (de) | 1997-06-18 | 1999-02-11 | Deutsches Krebsforsch | HBV-gerichtete Antisense-Nukleinsäuren |
| CA2306733A1 (en) | 1997-10-28 | 1999-05-06 | American Home Products Corporation | Compositions and methods for delivery of genetic material |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CA2319757C (en) * | 1998-01-27 | 2008-01-08 | Cytocell Limited | Method for detection of nucleic acid target sequences involving in vitro transcription from an rna promoter |
| JP2002506801A (ja) | 1998-03-16 | 2002-03-05 | ザ、プロクター、エンド、ギャンブル、カンパニー | 哺乳類の皮膚のセルライトを軽減する方法 |
| WO2000063364A2 (en) | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
| US6533250B2 (en) | 1999-10-15 | 2003-03-18 | W. Eugene Arthur | Energy dissipating system for a concrete roadway barrier |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| EP1309726B2 (en) * | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| US7439016B1 (en) * | 2000-06-15 | 2008-10-21 | Digene Corporation | Detection of nucleic acids by type-specific hybrid capture method |
| US6680059B2 (en) * | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
| US6443403B1 (en) | 2000-09-11 | 2002-09-03 | Panduit Corp. | Cable routing clamp and method of application |
| JP2002335968A (ja) | 2001-05-16 | 2002-11-26 | Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho | 新規転写因子、その遺伝子及びその結合ｄｎａ配列 |
| ES2566561T3 (es) | 2001-07-12 | 2016-04-13 | University Of Massachusetts | Producción in vivo de ARN pequeños de interferencia que median el silenciamiento génico |
| WO2003013293A2 (en) | 2001-08-03 | 2003-02-20 | Michael Van Der Sleesen | Protective garment |
| US7103761B2 (en) | 2001-08-07 | 2006-09-05 | Hewlett-Packard Development Company, Lp. | Server system with multiple management user interfaces |
| US6673661B1 (en) | 2002-12-20 | 2004-01-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Self-aligned method for forming dual gate thin film transistor (TFT) device |
| EP2071030A3 (en) * | 2003-01-24 | 2009-07-22 | Tokyo Metropolitan Organization for Medical Research | Oligoribonucleotide or peptide nucleic acid which inhibits action of hepatitis C virus |
| CN1257284C (zh) | 2003-03-05 | 2006-05-24 | 北京博奥生物芯片有限责任公司 | 一种体外阻断乙肝病毒表达的方法 |
| BRPI0411219A (pt) | 2003-06-12 | 2006-07-18 | Nucleonics Inc | seqüências de hbv e hcv conservadas úteis para silenciamento de gene |
| WO2006033756A2 (en) * | 2004-08-23 | 2006-03-30 | Nucleonics, Inc. | Multiple rna polymerase iii promoter expression constructs |
| JP2015086965A (ja) | 2013-10-31 | 2015-05-07 | 株式会社エクセディ | フライホイール組立体 |
-
2004
- 2004-06-10 BR BRPI0411219-9A patent/BRPI0411219A/pt not_active Application Discontinuation
- 2004-06-10 US US10/560,377 patent/US8350021B2/en not_active Expired - Fee Related
- 2004-06-10 AU AU2004263832A patent/AU2004263832B2/en not_active Expired
- 2004-06-10 EP EP18192425.9A patent/EP3470518A1/en active Pending
- 2004-06-10 CA CA3040025A patent/CA3040025C/en not_active Expired - Lifetime
- 2004-06-10 SI SI200432456T patent/SI2270162T1/sl unknown
- 2004-06-10 EP EP04776661A patent/EP1631670B1/en not_active Expired - Lifetime
- 2004-06-10 EP EP10180048.0A patent/EP2270162B1/en not_active Expired - Lifetime
- 2004-06-10 SG SG2007044373A patent/SG173218A1/en unknown
- 2004-06-10 EP EP10180047A patent/EP2284268A3/en not_active Withdrawn
- 2004-06-10 CA CA2528510A patent/CA2528510C/en not_active Expired - Lifetime
- 2004-06-10 WO PCT/US2004/019229 patent/WO2005014806A2/en not_active Ceased
- 2004-06-10 DK DK10180048.0T patent/DK2270162T3/en active
- 2004-06-10 JP JP2006533810A patent/JP4980716B2/ja not_active Expired - Fee Related
- 2004-06-10 CN CNA2004800228949A patent/CN1836042A/zh active Pending
- 2004-06-10 HU HUE10180048A patent/HUE042261T2/hu unknown
-
2005
- 2005-11-30 IL IL172268A patent/IL172268A0/en unknown
-
2011
- 2011-07-04 JP JP2011148461A patent/JP5593279B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1631670A2 (en) | 2006-03-08 |
| CN1836042A (zh) | 2006-09-20 |
| SI2270162T1 (sl) | 2019-03-29 |
| WO2005014806A2 (en) | 2005-02-17 |
| AU2004263832A1 (en) | 2005-02-17 |
| EP2284268A3 (en) | 2012-05-30 |
| WO2005014806A3 (en) | 2005-12-01 |
| CA2528510A1 (en) | 2005-02-17 |
| CA3040025C (en) | 2023-01-10 |
| IL172268A0 (en) | 2006-04-10 |
| CA2528510C (en) | 2019-06-04 |
| JP4980716B2 (ja) | 2012-07-18 |
| HUE042261T2 (hu) | 2019-06-28 |
| JP5593279B2 (ja) | 2014-09-17 |
| US20080070854A1 (en) | 2008-03-20 |
| EP1631670B1 (en) | 2012-08-08 |
| CA3040025A1 (en) | 2005-02-17 |
| EP2270162B1 (en) | 2018-10-03 |
| DK2270162T3 (en) | 2019-01-21 |
| JP2007503474A (ja) | 2007-02-22 |
| US8350021B2 (en) | 2013-01-08 |
| JP2011224013A (ja) | 2011-11-10 |
| SG173218A1 (en) | 2011-08-29 |
| EP2270162A3 (en) | 2012-05-30 |
| EP2284268A2 (en) | 2011-02-16 |
| EP3470518A1 (en) | 2019-04-17 |
| EP2270162A2 (en) | 2011-01-05 |
| AU2004263832B2 (en) | 2010-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0411219A (pt) | seqüências de hbv e hcv conservadas úteis para silenciamento de gene | |
| BR0111827A (pt) | Vìrus de rna isolado, recombinantemente gerado, não segmentado, de sentido negativo, de filamento único do gênero morbillivìrus, composição imunogênica, método para imunizar um indivìduo para induzir proteção contra o dito vìrus, método para reduzir a repressão causada por uma proteìna v do gênero morbillivìrus, sequência de nucleotìdeos isolada, composição, e, método para produzir um morbillivìrus infeccioso | |
| DE60319820D1 (de) | Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien | |
| WO2010136981A3 (en) | Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof | |
| MY176918A (en) | N- [ (2 ' r) -2' -deoxy-2' -fluoro-2' -methyl-p-phenyl-5' -uridylyl] - l-alanine 1-methylethyl ester and process for its production | |
| DK1554301T3 (da) | Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR | |
| BR9813485A (pt) | Virús da sìndrome de emaciação ou enfraquecimento gradual multisistêmico pós-desmame de porcos. | |
| PT100472A (pt) | Sequencias genomicas do virus da hepatite c e composicoes farmaceuticas que as contem, para diagnostico e terapeutica da hepatite c | |
| BR112012024923A2 (pt) | "fosforamidatos de nucleosídeo, composição, comprimido, e seus usos" | |
| BR9712592A (pt) | Processo para gerar um clone infeccioso, ácido nucléico recombinante, molécula do mesmo, vìrus de rna modificado, célula infectada com o mesmo, vacina, proteìna e/ou antìgeno, e, ensaio diagnóstico | |
| WO2006069064A3 (en) | Conserved hbv and hcv sequences useful for gene silencing | |
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| WO2006121464A3 (en) | Compositions for treating respiratory viral infections and their use | |
| BR0316291A (pt) | Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv | |
| BR0012512A (pt) | Genes de calicivìrus felino e vacinas notadamente vacinas recombinadas | |
| BR9913333A (pt) | Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos | |
| Ma et al. | Analyses of nucleotide, codon and amino acids usages between peste des petits ruminants virus and rinderpest virus | |
| EP1556493A4 (en) | NEW COMPLETE GENETIC DNA OF THE JAPANESE CEPHALITIS VIRUS, INFECTIOUS JEV CDNA FROM AND THEIR USE | |
| Miller et al. | The nucleotide sequence of RNA-1 of Indian peanut clump furovius | |
| BRPI0607487A2 (pt) | virus rna deficientes em replicação como vacinas | |
| WO2004070002A3 (en) | Cell lines and host nucleic acid sequences related to infectious disease | |
| EA200401362A1 (ru) | Антивирусная терапия, основанная на противодействии рнк | |
| Hassab Elnabi | New strategies for treatment of COVID-19 and evolution of SARS-CoV-2 according to biodiversity and evolution theory | |
| BR0211178A (pt) | Cadeias nucleotìdicas quiméricas, proteìnas quiméricas, preparação farmacêutica, e, método diagnóstico | |
| DOP2024000204A (es) | Composiciones y métodos para la prevención y el tratamiento de la infección por el virus de la rabia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 15/11 Ipc: A61K 48/00 (2006.01), C12N 15/11 (2006.01), A61P 3 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |